NCT00103428View on ClinicalTrials.gov

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

August 31, 2004

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

CG7870

Trial Locations (1)

75246

Mary Crowley Medical Research Center, Dallas

Sponsors

Lead Sponsor

Cell Genesys
All Listed Sponsors
lead

Cell Genesys

INDUSTRY

NCT00103428 - Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter